X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3441) 3441
Publication (317) 317
Book Review (50) 50
Book Chapter (7) 7
Conference Proceeding (7) 7
Book / eBook (5) 5
Data Set (1) 1
Dissertation (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2944) 2944
male (2442) 2442
index medicus (2105) 2105
adult (2086) 2086
female (1305) 1305
middle aged (1119) 1119
pharmacology & pharmacy (1088) 1088
healthy volunteers (1028) 1028
young adult (1020) 1020
pharmacokinetics (701) 701
adolescent (510) 510
cross-over studies (490) 490
healthy-subjects (477) 477
aged (474) 474
neurosciences (474) 474
analysis (444) 444
healthy-volunteers (411) 411
double-blind method (402) 402
psychiatry (336) 336
administration, oral (321) 321
research (317) 317
area under curve (304) 304
dose-response relationship, drug (295) 295
pharmacology (294) 294
medicine & public health (268) 268
drug interactions (251) 251
pharmacology/toxicology (250) 250
endocrinology & metabolism (237) 237
healthy (235) 235
animals (230) 230
metabolism (221) 221
physiology (221) 221
health aspects (219) 219
safety (217) 217
studies (217) 217
healthy male-subjects (214) 214
nutrition & dietetics (214) 214
time factors (212) 212
pharmacodynamics (210) 210
exercise (209) 209
internal medicine (207) 207
clinical neurology (205) 205
reference values (205) 205
physiological aspects (199) 199
sex factors (189) 189
sport sciences (178) 178
risk factors (167) 167
double-blind (161) 161
healthy subjects (160) 160
age (157) 157
body mass index (154) 154
clinical trials (152) 152
healthy-men (147) 147
drug dosages (145) 145
aged, 80 and over (143) 143
biomedicine (143) 143
article (142) 142
dosage and administration (142) 142
half-life (142) 142
medicine (139) 139
models, biological (138) 138
magnetic resonance imaging (135) 135
drug administration schedule (132) 132
reproducibility of results (131) 131
biological availability (129) 129
age factors (127) 127
drug therapy (127) 127
blood pressure (126) 126
care and treatment (125) 125
usage (125) 125
brain (124) 124
women (124) 124
diet (123) 123
bioavailability (122) 122
analysis of variance (121) 121
research article (121) 121
plasma (118) 118
adults (116) 116
pharmacotherapy (115) 115
disease (113) 113
glucose (113) 113
obesity (113) 113
cross-sectional studies (111) 111
hypertension (109) 109
peripheral vascular disease (108) 108
efficacy (107) 107
metabolites (107) 107
treatment outcome (106) 106
biochemistry & molecular biology (105) 105
genotype (104) 104
insulin (103) 103
risk (103) 103
heart rate (100) 100
population (100) 100
toxicology (100) 100
child (99) 99
diabetes (99) 99
original (99) 99
sex characteristics (99) 99
exercise - physiology (98) 98
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3369) 3369
Japanese (58) 58
Korean (7) 7
Chinese (5) 5
German (5) 5
Portuguese (3) 3
Croatian (1) 1
French (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 10/2018, Volume 82, Issue 4, pp. 615 - 623
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 04/2017, Volume 102, Issue 4, pp. 1325 - 1332
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2017, Volume 12, Issue 3, p. e0173686
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 09/2017, Volume 39, Issue 9, pp. 1849 - 1857
Tedizolid phosphate is a next-generation oxazolidinone prodrug that is transformed into the active moiety tedizolid. Its indication is acute bacterial skin and... 
healthy Korean subjects | pharmacokinetics | oxazolidinone | tedizolid | bioavailability | MULTIDRUG-RESISTANT | RESISTANT STREPTOCOCCUS-PNEUMONIAE | ANTIMICROBIAL RESISTANCE | METHICILLIN-RESISTANT | ASIAN COUNTRIES | ACUTE BACTERIAL SKIN | SKIN-STRUCTURE INFECTIONS | SOUTH-KOREA | PHARMACOLOGY & PHARMACY | STAPHYLOCOCCUS-AUREUS | Prodrugs - administration & dosage | Organophosphates - adverse effects | Anti-Bacterial Agents - blood | Humans | Half-Life | Biological Availability | Male | Healthy Volunteers | Young Adult | Oxazoles - blood | Oxazoles - adverse effects | Adult | Anti-Bacterial Agents - adverse effects | Republic of Korea | Organophosphates - administration & dosage | Organophosphates - pharmacokinetics | Double-Blind Method | Administration, Oral | Organophosphates - blood | Oxazoles - pharmacokinetics | Cross-Over Studies | Prodrugs - adverse effects | Administration, Intravenous | Prodrugs - pharmacokinetics | Oxazoles - administration & dosage | Anti-Bacterial Agents - pharmacokinetics | Anti-Bacterial Agents - administration & dosage | Phosphates | Safety and security measures | Analysis | Pathogens | Bacterial infections | Oral administration | Dietary supplements | Staphylococcus infections | Pharmacology | FDA approval | Bioavailability | Metabolism | Switching | Proteins | Multidrug resistant organisms | Antibiotics | Metabolites | Protein synthesis | Linearity | Skin | Kinetics | Pharmacokinetics | Drug therapy | Drug dosages
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 6/2018, Volume 74, Issue 6, pp. 745 - 754
Ticagrelor, the first reversible P2Y12 receptor antagonist, exhibits faster onset and offset of antiplatelet effects and more consistent platelet inhibition... 
Biomedicine | Maximal platelet inhibition | Simulation | CYP3A53 | CYP3A41G | AR-C124910XX | Pharmacology/Toxicology | Ticagrelor | Population pharmacokinetics and pharmacodynamics | Turnover model | AZD6140 | ANTAGONIST | SAFETY | GENOTYPE | OPEN-LABEL | CLOPIDOGREL | INHIBITION | STANDARD-DOSE TICAGRELOR | TOLERABILITY | PHARMACOLOGY & PHARMACY | P2Y RECEPTOR | Purinergic P2Y Receptor Antagonists - pharmacology | Adenosine - pharmacokinetics | Purinergic P2Y Receptor Antagonists - administration & dosage | Humans | Asian Continental Ancestry Group - genetics | Purinergic P2Y Receptor Antagonists - pharmacokinetics | Male | Purinergic P2Y Receptor Antagonists - blood | Adenosine - pharmacology | Adenosine - administration & dosage | Healthy Volunteers | Dose-Response Relationship, Drug | Young Adult | Adenosine - blood | Cytochrome P-450 CYP3A - genetics | Models, Biological | Adenosine - analogs & derivatives | Adult | Platelet Aggregation - drug effects | Polymorphism, Single Nucleotide | Blood Platelets - drug effects | Single nucleotide polymorphisms | Coronary heart disease | Analysis | Cardiac patients | Cytochrome P-450 | Pharmacodynamics | Computer simulation | Coronary artery | Cardiovascular disease | Population studies | Pharmacology | Single-nucleotide polymorphism | Dosage | Coronary artery disease | Optimization | Mens health | Blood platelets | Biotransformation | Clopidogrel | Inhibition | Pharmacokinetics | Platelets | Heart diseases | Asians
Journal Article
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2017, Volume 40, Issue 1, pp. 88 - 96
Journal Article